🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

13 recruiting trials

for Limited-stage Small Cell Lung Cancer (LS-SCLC)

Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT NCT05623267Phase 2, Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Sugemalimab, Placebo Serplulimab Combined With CCRT for LS-SCLC. NCT06295926Phase 21 site📍 Beijing Peking Union Medical College Hospital · Tests: Serplulimab Durvalumab as Consolidation for Patients LS-SCLC NCT07055581Phase 22 sites📍 Zhengzhou📍 Wuhan Qian Chu · Tests: Induction Durvalumab +etoposide/platinum +Radiochemotherapy+ durvalumab maintenance Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC) NCT06911606Phase 21 site📍 Guangzhou Guangdong Provincial People's Hospital · Tests: 4 cycles of Serplulimab combined with etoposide and carboplatin or cisplatin Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) NCT06095583Phase 376 sites📍 Harbin📍 Changsha📍 Nanchang Shanghai Junshi Bioscience Co., Ltd. · Tests: Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC NCT07815223Phase 21 site📍 Yantai Yantai Yuhuangding Hospital · Tests: Tislelizumab + Anlotinib A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC NCT07798947Phase 21 site📍 Jinan Shanghai Hengrui Pharmaceutical Co., Ltd. · Tests: SHR-7787 Injection, SHR-1316 Omitting CTV for Primary Tumor in LS-SCLC NCT07008716Phase 32 sites📍 Guangzhou📍 Hangzhou Sun Yat-sen University · Tests: Radiation Therapy, Etoposide + carboplatin; Etoposide + cisplatin, Creating CTV for primary tumor, prophylactic cranial… Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC) NCT06943235Phase 21 site📍 Shanghai Fudan University · Tests: Probiotics, concurrent Hyperfractionated Radiotherapy, Immunotherapy Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer NCT06719700Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Chemotherapy, Immunotherapy, Angio-immuno kinase inhibitor, radiotherapy, Prophylactic Cranial Irradiation Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy NCT06869239n/a1 site📍 Beijing Peking University Cancer Hospital & Institute · Tests: Etoposide + cisplatin/carboplatin, Thoracic radiotherapy, Prophylactic cranial irradiation (PCI), PD-L1 inhibitor A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy NCT07091305Phase 21 site📍 Shanghai Shanghai Chest Hospital · Tests: QL1706 (bispecific antibody targeting PD-1 and CLTA-4) A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy NCT07559786Phase 22 sites📍 Zhengzhou📍 Zhengzhou Henan Cancer Hospital · Tests: CCRT(Employed residual field irradiation(RFI)), CCRT(Involved-Field Radiotherapy (IFRT))
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy